top of page

South Africa (SAHPRA) Guidance on How to Submit Variation Applications

Writer's picture: Sharan MuruganSharan Murugan

The purpose of this document is to inform applicants on how to submit variations to the South African Health Products Regulatory Authority (SAHPRA) for Category A and C medicines as well as what to expect during the variation evaluation process.


SAHPRA has adopted the European Union (EU) variation classification guideline, with the full details (including the associated exceptions) published in the Variations Addendum for Human and Veterinary Medicines

The purpose of the Digital Variations Portal is two-fold:

  • Facilitate the submission and processing of Type I variation applications

  • Provide an electronic database of implemented variations for use by Port Health, without the need for industry to wait for amended registration certificates

For variations submitted in eCTD format for the first time, applicants will be required to include a baseline as part of the dossier. For variations submitted in eSubmission format, applicants may opt to include a baseline where relevant and practical.


Type I eSubmission variation applications and eSubmission response submissions should be submitted via the Digital Variations Portal (DVP). The DVP is not applicable to the Biological medicines & veterinary medicines.


Type I eCTD, eCTD response submissions and all Type II variation applications should be submitted via the File Transfer Protocol (FTP).


Click the LINK for more detailed information on the BAU (Business As Usual ) VARIATIONS COMMUNICATION


Comments


I Sometimes Send Newsletters

Thanks for submitting!

  • LinkedIn
  • Facebook
  • Twitter
  • Instagram

DISCLAIMER

The views expressed in this publication do not necessarily reflect the views of any guidance of government, health authority, it's purely my understanding. This Blog/Web Site is made available by a regulatory professional, is for educational purposes only as well as to give you general information and a general understanding of the pharmaceutical regulations, and not to provide specific regulatory advice. By using this blog site you understand that there is no client relationship between you and the Blog/Web Site publisher. The Blog/Web Site should not be used as a substitute for competent pharma regulatory advice and you should discuss from an authenticated regulatory professional in your state.  We have made every reasonable effort to present accurate information on our website; however, we are not responsible for any of the results you experience while visiting our website and request to use official websites.

bottom of page